Moreover, although MMR deficiency itself is a common event for all carcinogenic pathways described in LS-CRC, patients have heterogenous risks of developing hypermutated polyps which highly express neoantigens or polyps with a low mutational burden and therefore a lower expression of neoantigens depending on the mutation of the MMR gene and the carcinogenic pathway involved [50,67]. The gene discussed is MRC1; the disease is hyperinsulinemic hypoglycemia, familial, 4.